KIR2DL3/KIR2DS2 Antibody

What are the key differences between KIR2DL3, KIR2DL2, and KIR2DS2?

KIR2DL3 and KIR2DL2 are inhibitory receptors that recognize HLA-C molecules, while KIR2DS2 is an activating receptor. Despite sharing approximately 94% sequence identity, these receptors have distinct functional properties:

• KIR2DL2 and KIR2DL3 segregate as alleles of a single locus but are inherited on different KIR haplotypes

• KIR2DS2 is in linkage disequilibrium with KIR2DL2, not KIR2DL3

• KIR2DL2 has been shown to epistatically suppress the expression of KIR2DL1, a phenomenon not observed with KIR2DL3

• In terms of binding specificity, KIR2DL2 exhibits greater avidity than KIR2DL3 for HLA-C1 group allotypes and has broader cross-reactivity with HLA-C2 allotypes

These differences correlate with varying clinical outcomes. For example, in the presence of HLA-C1 alleles, KIR2DL3 but not KIR2DL2 has been associated with clearance of hepatitis C infection and progression of ulcerative colitis .

Why is it challenging to develop antibodies specific for KIR2DS2?

Developing antibodies that specifically detect KIR2DS2 is challenging due to the high sequence homology between KIR2DS2 and the inhibitory receptors KIR2DL2 and KIR2DL3 . Most commercially available antibodies, such as CH-L, DX27, and GL-183, cross-react with KIR2DS2, KIR2DL2, and KIR2DL3 .

Previous attempts to develop KIR2DS2-specific antibodies faced limitations:

• Antibody clone 1F12 can distinguish KIR2DS2 from KIR2DL2 but also binds KIR2DL3, limiting its utility to donors with a KIR2DL2/KIR2DS2 homozygous genotype who lack KIR2DL3

• Many antibodies recognize common epitopes shared between these closely related receptors due to their structural similarities

These challenges highlight the need for innovative approaches, such as antibody combinations or epitope-specific antibody development, to accurately identify KIR2DS2-expressing cells.

What experimental methods can be used to verify KIR genotypes in research subjects?

When working with KIR antibodies, it is essential to know the KIR genotype of research subjects. Several methods can be employed:

• PCR with sequence-specific primers (PCR-SSP): This is the most commonly used method, as referenced in the studies examining KIR2DL3/KIR2DL2/KIR2DS2 genotypes

• Next-generation sequencing (NGS): Provides comprehensive KIR gene content and allelic variation

• Flow cytometry with known specificity antibodies: Can be used as a complementary approach to validate genetic findings

For accurate interpretation of antibody binding results, researchers should determine whether subjects are:

• KIR2DL3 homozygous

• KIR2DL2/KIR2DS2 homozygous

• KIR2DL3/KIR2DL2/KIR2DS2 heterozygous

These distinct genotypes produce different antibody staining patterns that influence experimental design and data interpretation .

What novel antibody combinations can effectively differentiate KIR2DS2high NK cells from KIR2DL3/KIR2DL2high NK cells?

Recent research has identified a novel antibody combination that can distinguish NK cells with relatively high expression of KIR2DS2 from those predominantly expressing KIR2DL3/KIR2DL2 . This approach utilizes:

• Antibody clone CH-L: Binds to KIR2DL2, KIR2DL3, and KIR2DS2

• Antibody clone REA147: Binds to KIR2DL2 and KIR2DL3, but shows no significant binding to KIR2DS2

Using this combination, researchers can identify three distinct populations:

• KIR2DL3/KIR2DL2high cells: Positive for both CH-L and REA147

• KIR2DS2high cells: Positive for CH-L but negative for REA147

• KIR2DL3/KIR2DL2/KIR2DS2-negative cells: Negative for both antibodies

This separation is sufficient to examine primary human NK cell activation in response to KIR2DS2-specific ligands .

This approach has been validated using both transfected NK cell lines and primary human samples, making it applicable across various experimental contexts .

How do KIR2DS2high NK cells from cancer patients compare functionally to KIR2DL3/KIR2DL2high NK cells in response to tumor-targeting antibodies?

KIR2DS2high NK cells from cancer patients demonstrate enhanced functional responses compared to other NK cell subsets when exposed to tumor-targeting antibodies . Key findings include:

• Against hepatocellular carcinoma (HCC) cells treated with cetuximab or avelumab, KIR2DS2high NK cells showed significantly higher expression of CD107a (a degranulation marker) and IFNγ compared to KIR2DL3/KIR2DL2high and KIR2DL3/KIR2DL2/KIR2DS2-negative NK cell populations

• In chronic lymphocytic leukemia (CLL) models with anti-CD20 antibodies (rituximab and obinutuzumab), KIR2DS2high NK cells exhibited superior CD107a and IFNγ expression compared to other NK cell subsets

• This enhanced functionality was maintained even in the presence of signals mimicking the lymph node microenvironment (CD40L and IL-4)

• In HCC patients, CD16 expression was not significantly higher on KIR2DS2high NK cells compared to KIR2DL3/KIR2DL2high NK cells, suggesting that the enhanced functionality is not simply due to increased CD16 expression

These findings indicate that KIR2DS2high NK cells represent a highly active NK cell subset in cancer patients that could potentially be targeted for enhanced immunotherapeutic approaches.

What methodological considerations are important when designing experiments to evaluate KIR2DS2-specific ligands?

When designing experiments to evaluate KIR2DS2-specific ligands, several critical methodological considerations should be addressed:

• Antibody selection and validation:

  • Use the CH-L and REA147 antibody combination to accurately identify KIR2DS2high NK cells

  • Validate antibody specificity using transfected cell lines expressing individual KIR receptors

• Experimental controls:

  • Include KIR2DL3 homozygous donors as negative controls for KIR2DS2-specific responses

  • Test KIR2DL3/KIR2DL2high NK cells in parallel with KIR2DS2high NK cells from the same donors to control for donor-specific variations

• Ligand presentation methods:

  • For peptide-based ligands, use appropriate HLA-C-expressing cell lines (such as 721.221 cells transfected with specific HLA-C alleles)

  • Control for peptide loading efficiency and HLA-C expression levels

• Functional readouts:

  • Include multiple activation markers (e.g., CD107a for degranulation and IFNγ for cytokine production)

  • Subtract background activation (no target control) from experimental conditions

• Donor genotyping:

  • Perform KIR and HLA genotyping to account for genetic variations affecting NK cell education and functional responses

Following these considerations will enhance the reliability and reproducibility of experiments investigating KIR2DS2-specific ligands.

How does ex vivo expansion affect the functional properties of KIR2DS2high NK cells?

The ex vivo expansion process significantly alters the functional properties of KIR2DS2high NK cells, with important implications for NK cell-based therapies :

• Loss of enhanced reactivity: Following ex vivo expansion in IL-2 or IL-12/15/18, KIR2DS2high NK cells lose their superior activation against HLA-expressing targets compared to NK cells lacking KIR2DL3/KIR2DL2/KIR2DS2 expression

• Receptor expression changes: Ex vivo expansion in IL-2 has been shown to alter NK cell function, receptor expression, and gene expression. After expansion, researchers identified significantly increased expression of activating receptors NKp30, NKp46, and NKG2D across all NK cell subpopulations, including KIR2DS2high cells

• Functional implications: The changes in receptor expression may override the native capacity for KIR2DS2+ NK cells to possess enhanced effector functions evident in freshly isolated cells

• Target-specific effects:

  • Against HLA-null target cells, expanded KIR2DS2high NK cells showed no enhanced reactivity

  • The loss of superior function against HLA-expressing targets was likely due to reduced inhibitory KIR signaling

This data suggests that while KIR2DS2 is an attractive target for in vivo targeted NK cell immunotherapeutic strategies, its functional advantage is lost following ex vivo expansion processes commonly used in adoptive transfer approaches .

What are the structural differences between KIR2DL2 and KIR2DL3 that influence their HLA-C binding properties?

Crystal structure analyses have revealed key structural differences between KIR2DL2 and KIR2DL3 that influence their HLA-C binding properties :

• Docking modality: KIR2DL2 differs from KIR2DL3 in its docking modality over HLA-C*07:02, which correlates with variability in recognition of HLA-C1 allotypes

• Binding geometry: Different binding geometries between KIR2DL2 and KIR2DL3 contribute to distinguishing functional recognition of HLA-C1

• Peptide sensitivity: The structural differences affect how these receptors respond to changes in the peptide content of HLA-C molecules:

  • KIR2DL2 has been shown to interact with a broader array of peptides compared to KIR2DL3

  • These differences impact the quality of inhibitory signaling and ultimately NK cell function

• Structural plasticity: The structural plasticity of KIR2DL2 and KIR2DL3 enables altered docking on HLA-C molecules, affecting downstream signaling events

These structural differences cannot be predicted through sequence analysis alone, highlighting the importance of structural studies in understanding KIR-HLA interactions .

How can viral peptides be utilized to validate the functionality of KIR2DS2high NK cells?

Viral peptides have proven valuable for validating the functionality of KIR2DS2high NK cells identified using the novel antibody combination approach :

• Viral helicase peptides:

  • LNPSVAATL (LNP) derived from hepatitis C virus

  • IVDLMCHATF (IVD) derived from dengue virus

  • Both peptides specifically bind and stimulate KIR2DS2

• Experimental approach:

  • Present peptides using HLA-C-expressing cell lines

  • Measure NK cell degranulation (CD107a expression) in different NK cell subsets

• Expected results:

  • KIR2DS2high NK cells (CH-L positive, REA147 negative) show increased degranulation in response to LNP or IVD peptides

  • KIR2DL3/KIR2DL2high NK cells (CH-L positive, REA147 positive) show no significant change in degranulation

  • KIR2DL3-positive NK cells from KIR2DL3 homozygous donors also show no response to these peptides

This approach provides a functional validation that the antibody-defined KIR2DS2high population truly represents NK cells with predominant KIR2DS2 activity, supporting the use of this antibody combination in identifying functionally relevant KIR2DS2-expressing NK cells .

What strategies can be employed to differentiate between the contributions of KIR2DL2 and KIR2DS2 in functional NK cell assays?

• Combined antibody approach:

  • Use the 1F12 monoclonal antibody (which recognizes KIR2DL3 and KIR2DS2) alongside GL183 (KIR2DL2/L3/S2) and REA147 (KIR2DL3) to discriminate between KIR2DL3+, KIR2DL2+KIR2DS2−, and KIR2DS2+ populations

• Donor selection:

  • Compare responses between donors with different KIR genotypes:

    • KIR2DL3 homozygous donors

    • KIR2DL2/S2 homozygous donors

    • KIR2DL3/L2/S2 heterozygous donors

• Target cell manipulation:

  • Use HLA-C transfectants with different C1/C2 allotypes to exploit the differential binding preferences of KIR2DL2 and KIR2DS2

  • Use HLA-negative cell lines (such as 721.221) to eliminate inhibitory signals through KIR2DL2

• Functional readouts:

  • Compare activation markers in response to specific viral peptides known to trigger KIR2DS2 but not KIR2DL2

  • Analyze inhibitory capacity against different HLA-C allotypes to distinguish KIR2DL2-mediated effects

By employing these strategies, researchers can better differentiate the contributions of these closely related receptors in NK cell functional assays, leading to improved understanding of their individual roles in immune responses.